Initial Therapy — Moderate to Severe Plaque Psoriasis
Covered when ALL of the following are met:
ALL of the following
Member is 6 years of age or older.
ONE of the following
Member has previously received a biologic or targeted synthetic drug (e.g., Sotyktu, Otezla) indicated for the treatment of moderate to severe plaque psoriasis.
ONE of the following plaque psoriasis severity or treatment criteria
Crucial body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, or intertriginous areas) are affected.
At least 10% of the body surface area (BSA) is affected.>= 10% BSA
ALL of the following
At least 3% of the BSA is affected.>= 3% BSA
ONE of the following
Member has had an inadequate response or intolerance to phototherapy (e.g., UVB or PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin.
Member has a clinical reason to avoid pharmacologic treatment with methotrexate, cyclosporine, and acitretin (see Appendix A).
Initial Therapy — Active Psoriatic Arthritis
Covered when ALL of the following are met:
ALL of the following
Member is 6 years of age or older.
ONE of the following
Member has previously received a biologic or targeted synthetic drug (e.g., Rinvoq, Otezla) indicated for active psoriatic arthritis.
ONE of the following disease criteria
ALL of the following
Member has mild to moderate active psoriatic arthritis.
Initial Therapy — Crohn's Disease
Authorization of 12 months may be granted when the requested medication is used for moderately to severely active Crohn's disease.
Member has moderately to severely active Crohn's disease.
Initial Therapy — Ulcerative Colitis
Authorization of 12 months may be granted when the requested medication is used for moderately to severely active ulcerative colitis.
Member has moderately to severely active ulcerative colitis.
Continuation Therapy — Plaque Psoriasis
Authorization of 12 months may be granted for all members, including new members, when ALL of the following are met:
ALL of the following
Member is using the requested medication for moderate to severe plaque psoriasis.
Positive clinical response evidenced by ONE of the following
Improvement in signs and symptoms of the condition.
Improvement from baseline in ONE of the following
Reduction in BSA affected.
Continuation Therapy — Psoriatic Arthritis
Authorization of 12 months may be granted for all members, including new members, when ALL of the following are met:
ALL of the following
Member is using the requested medication for psoriatic arthritis.
Positive clinical response evidenced by ONE of the following
Improvement in signs and symptoms of the condition.
Improvement from baseline in ONE or more of the following
Number of swollen joints.
Continuation Therapy — Crohn's Disease
Authorization of 12 months may be granted for all members, including new members, when ALL of the following are met:
ALL of the following
Member is using the requested medication for moderately to severely active Crohn's disease.
ONE of the following
Member achieves or maintains remission.
ALL of the following
Positive clinical response evidenced by ONE of the following
Continuation Therapy — Ulcerative Colitis
Authorization of 12 months may be granted for all members, including new members, when ALL of the following are met:
ALL of the following
Member is using the requested medication for moderately to severely active ulcerative colitis.
ONE of the following
Member achieves or maintains remission.
ALL of the following
Positive clinical response evidenced by ONE of the following
General Requirements
The following requirements apply to all indications:
ALL of the following
For persons naïve to biologic drugs or targeted synthetic drugs associated with an increased risk of tuberculosis, the member has a documented negative tuberculosis (TB) test, which may include a TB skin test (TST) or interferon-release assay (IGRA), within 12 months before initiating therapy.
If TB screening is positive, further testing has confirmed that there is no active disease (e.g., chest x-ray).
Latent TB treatment must be started before initiation of the requested medication.
Members currently receiving the requested medication as samples or through the manufacturer's patient assistance program must meet the criteria for initial approval.
Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.
Do not administer the requested medication to members with active TB infection. If latent TB disease is present, TB treatment must be started before initiation of the requested medication.
The requested medication cannot be used concomitantly with any other biologic drug or targeted synthetic drug for the same indication.
Skyrizi (risankizumab-rzaa) is considered not medically necessary for members who do not meet the criteria set forth above.